StockData
Lipella Pharmaceuticals Inc. logo

Lipella Pharmaceuticals Inc. (LIPO) stock

LIPOOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 6/30
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $2.27KP/E –Yield –

Lipella Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Lipella Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2025 was $3.57M, up 18.7% year over year. For fiscal 2024 it was $3.61M, up 18.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2024Dec 31, 2024$3.61M+18.9%
FY2023Dec 31, 2023$3.04M+19.3%
FY2022Dec 31, 2022$2.55M+74.9%
FY2021Dec 31, 2021$1.46M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2025Sep 30, 2025$720.97K-31.1%
Q2 FY2025Jun 30, 2025$791.58K+19.7%
Q1 FY2025Mar 31, 2025$993.48K+17.9%
Q4 FY2024Dec 31, 2024$1.06M+133.9%
Q3 FY2024Sep 30, 2024$1.05M+25.6%
Q2 FY2024Jun 30, 2024$661.56K-37.4%
Q1 FY2024Mar 31, 2024$842.60K+21.5%
Q4 FY2023Dec 31, 2023$454.20K-5.0%
Q3 FY2023Sep 30, 2023$833.26K+28.0%
Q2 FY2023Jun 30, 2023$1.06M+42.4%
Q1 FY2023Mar 31, 2023$693.73K+2.6%
Q4 FY2022Dec 31, 2022$478.10K–
Q3 FY2022Sep 30, 2022$650.95K–
Q2 FY2022Jun 30, 2022$742.66K–
Q1 FY2022Mar 31, 2022$675.96K–

More Lipella Pharmaceuticals figures

See a number that looks wrong?